Golimumab

CHEMBL1201833 Phase 4 Aprobado Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A fully human monoclonal antibody that inhibits tumor necrosis factor-alpha, a key driver of inflammation in conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. It is administered by subcutaneous injection monthly or intravenously for certain indications. Patients should be screened for tuberculosis and other infections before starting treatment.

Áreas terapéuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A fully human monoclonal antibody that inhibits tumor necrosis factor-alpha, a key driver of inflammation in conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. It is administered by subcutaneous injection monthly or intravenously for certain indications. Patients should be screened for tuberculosis and other infections before starting treatment.

Yes, Golimumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201833. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.